Market Overview
The hepatic fibrosis market encompasses diagnostic products, including serum biomarker assays, imaging modalities, and multi-modal panels, as well as emerging pharmacotherapies targeting fibrotic pathways. With a total market value around $20.6 billion in 2025, the sector covers tools used to detect, stage, and monitor liver scarring across diverse etiologies. The dedicated biomarkers segment is currently valued at roughly $425 million but is growing substantially faster than the overall market.
- •Overall hepatic fibrosis market valued at approximately $20.6 billion in 2025
- •Dedicated biomarker segment valued at roughly $425 million with ~20% CAGR
- •Market includes serum tests, imaging devices, and antifibrotic treatments
Growth Drivers
The market is propelled by the global surge in liver disease burden, particularly MASLD, which now affects a substantial portion of the adult population and represents a leading indication for liver transplantation. As clinical guidelines increasingly recommend non-invasive fibrosis assessment over biopsy, adoption of biomarker panels and elastography devices is accelerating. Simultaneously, the advancing pipeline of antifibrotic and MASH-targeted drugs is creating demand for companion biomarkers to monitor treatment response.
- •Rising prevalence of MASLD/MASH, hepatitis, and alcohol-related liver disease
- •Clinical shift from invasive liver biopsy toward non-invasive diagnostic alternatives
- •Growing pipeline of antifibrotic therapies increasing demand for companion biomarkers
Segmentation and Regional Analysis
The market divides into diagnostic segments, serum biomarkers such as enhanced liver fibrosis panels and hyaluronic acid assays, and imaging technologies including transient and shear-wave elastography, alongside a treatment segment for antifibrotic pharmacotherapies. North America commands the largest regional share due to high disease prevalence, advanced healthcare infrastructure, and favorable reimbursement environments. The Asia-Pacific region is emerging as the fastest-growing market, driven by rising obesity rates, expanding diagnostic access, and improving healthcare expenditure.
- •Serum biomarkers and elastography imaging represent the primary diagnostic categories
- •North America leads in market share due to disease prevalence and healthcare infrastructure
- •Asia-Pacific is the fastest-growing regional market
Trends and Outlook
What are the recent trends and outlook?
Artificial intelligence integration with imaging and biomarker datasets is emerging as a transformative development, enabling automated fibrosis staging and enhanced diagnostic precision. Multi-modal biomarker panels that combine serum markers, imaging measurements, and genetic risk profiles are gaining clinical acceptance as the preferred approach for comprehensive liver disease assessment. The convergence of diagnostics and therapeutics, particularly companion biomarkers for emerging antifibrotic drugs, is anticipated to drive significant market expansion and reshape competitive positioning over the coming decade.
- •AI-powered diagnostic platforms are improving fibrosis staging accuracy and efficiency
- •Multi-modal biomarker panels are becoming the emerging clinical standard
- •Companion diagnostics linked to antifibrotic drug pipelines represent a major growth opportunity
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.